(redirected from Pneumococcal polysaccharide vaccine)
Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.
Related to Pneumococcal polysaccharide vaccine: pneumococcal vaccine, Pneumococcal conjugate vaccine


A vaccine that is given to splenectomy patients to protect them against bacterial infections. Other vaccines include Pnu-Imune and Menomune.
Mentioned in: Splenectomy

pneumovax (nōōˑ·mō·vaksˈ),

n a vaccine for bacterial pneumonia that comprises polysaccharide compounds derived from 23 species of
Pneumococcus bacteria. Also called
pneumococcal polysaccharide vaccine, pneuomococcal vaccine, pneumococcal vaccine polyvalent, Pneumovax II, or
Pneumovax 23.
Enlarge picture
References in periodicals archive ?
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
0 PCR positive nasopharyngeal swab specimen for Streptococcus pneumoniae serotype 4 * PCV7, 7-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine.
The effectiveness of Prevnar 13[R] when given less than 5 years after the 23-valent pneumococcal polysaccharide vaccine is not known
For example, the pneumococcal polysaccharide vaccine that was approved in 1977 helped protect against 14 pneumococcal disease serotypes.
In these Phase 3 trials, vaccination with Prevnar 13 was shown to induce a functional antibody response to the 13 serotypes contained in the vaccine in adults 50 years of age and older, including individuals previously vaccinated with the conventional pneumococcal polysaccharide vaccine (PPSV) and those naove to pneumococcal vaccines.
However, patients on combination therapy showed decreased responses to both the 23-valent pneumococcal polysaccharide vaccine (PPV23), which measures T cell-independent humoral responses, and the neoantigen keyhole limpet hemocyanin (KLH), which tests T cell-dependent primary humoral responses.
Serotypes included in the 23-valent pneumococcal polysaccharide vaccine accounted for 92.
Poster Title: A Phase 3, Open-label Trial Evaluating the Safety and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Elderly Adults Who Received PCV13 Followed by 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) in a Prior Trial
This year's Adult Immunization Schedule includes the 2008 recommendation to use the pneumococcal polysaccharide vaccine in cigarette smokers and patients with asthma.
She had received pneumococcal polysaccharide vaccine in 1996.
Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously yesterday to recommend that adults ages 19 to 64 with asthma receive pneumococcal polysaccharide vaccine (PPSV23), known as PNEUMOVAX([R]) 23 (Pneumococcal Vaccine Polyvalent).
According to the Centers for Disease Control and Prevention, pneumococcal polysaccharide vaccine protects against 23 types of pneumococcal bacteria, including those most likely to cause serious disease.

Full browser ?